BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

5:29 PM
 | 
Aug 27, 2012
 |  BC Extra  |  Clinical News

T-DM1 meets OS endpoint

Roche (SIX:ROG; OTCQX:RHHBY) and its Genentech Inc. unit said T-DM1 met the co-primary endpoint of improving overall survival vs. Tykerb lapatinib plus Xeloda capecitabine in the Phase III EMILIA trial for second-line HER2-positive metastatic breast cancer. Genentech said detailed data will be presented at an...

Read the full 226 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >